Study Demonstrates LIVALO® Is an Efficacious Treatment for Achieving Lipid Goals

Study Demonstrates LIVALO® Is an Efficacious Treatment for Achieving Lipid Goals

22.10.2009

Study Demonstrates LIVALO® Is an Efficacious Treatment for Achieving Lipid Goals LIVALO Superior to Simvastatin in Reducing LDL-C When Comparing starting Doses

MONTGOMERY, Ala., October 22, 2009 - New Phase III data published today in "Current Medical Research and Opinion" highlight that the recommended starting dose of 2 mg of LIVALO (pitavastatin), a novel synthetic statin, was statistically superior to simvastatin at a dose of 20 mg over 12 weeks in reducing low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C) and total cholesterol (TC) in patients with primary hypercholesterolemia and combined dyslipidemia. With respect to LDL-C goal attainment, treatment with LIVALO was comparable to simvastatin according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines, but was superior based on European Atherosclerosis Society (EAS) guidelines.

Download Material

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more.

X